Diagnosing Lysosomal Storage Disorders: The GM2 Gangliosidoses

Patricia Hall1, Sara Minnich2, Claire Teigen3, Kimiyo Raymond2

1 Department of Human Genetics, Emory University, Atlanta, 2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, 3 GeneDx, Gaithersburg, Maryland
Publication Name:  Current Protocols in Human Genetics
Unit Number:  Unit 17.16
DOI:  10.1002/0471142905.hg1716s83
Online Posting Date:  October, 2014
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

The GM2 gangliosidoses are a group of autosomal recessive lysosomal storage disorders caused by defective β‐hexosaminidase. There are three clinical conditions in this group: Tay‐Sachs disease (TSD), Sandhoff disease (SD), and hexosaminidase activator deficiency. The three conditions are clinically indistinguishable. TSD and SD have been identified with infantile, juvenile, and adult onset forms. The activator deficiency is only known to present with infantile onset. Diagnosis of TSD and SD is based on decreased hexosaminidase activity and a change in the percentage of activity between isoforms. There are no biochemical tests currently available for activator deficiency. This unit provides a detailed procedure for identifying TSD and SD in affected individuals and carriers from leukocyte samples, the most robust sample type available. Curr. Protoc. Hum. Genet. 83:17.16.1‐17.16.8. © 2014 by John Wiley & Sons, Inc.

Keywords: Tay‐Sachs disease; Sandhoff disease; hexosaminidase; GM2 gangliosidosis

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Reagents and Solutions
  • Commentary
  • Literature Cited
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1:

  Materials
  • Whole blood specimen (ACD‐B): 10 ml is preferred, 5 ml is the minimum (samples must be shipped on wet ice; do not freeze whole blood)
  • 5% dextran solution (see recipe)
  • 0.7%, 0.9% (w/v) and 1.8% (w/v) NaCl (see recipe)
  • Protein assay kit (e.g., BioRad)
  • 0.6% bovine serum albumin (BSA; see recipe)
  • Substrate: 4‐methylumbelliferyl‐2‐acetamido‐2‐deoxy‐β‐D‐glucopyranoside (see recipe)
  • Stop buffer: 0.25 M glycine carbonate buffer (see recipe)
  • Standard: 4‐methylumbelliferone (see recipe)
  • 5‐ml conical polypropylene tubes
  • Refrigerated centrifuge
  • Probe sonicator (e.g., Misonix 3000)
  • 12 × 75–mm polystyrene tubes
  • Water bath (capable of 37°C and 51.5°C)
  • 96‐well flat‐bottom polystyrene microtiter plate (Corning Costar, cat. no. 3915) or 1.2‐ml polypropylene 8‐strip cluster tubes (plate selection should be compatible with fluorometer used)
  • Plate fluorometer
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Ben‐Yoseph, Y., Reid, J.E., Shapiro, B., and Nadler, H.L. 1985. Diagnosis and carrier detection of Tay‐Sachs disease: Direct determination of hexosaminidase A using 4‐methylumbelliferyl derivatives of beta‐N‐acetylglucosamine‐6‐sulfate and beta‐N‐acetylgalactosamine‐6‐sulfate. Am. J. Hum. Genet. 37:733‐740.
  Bley, A.E., Giannikopoulos, O.A., Hayden, D., Kubilus, K., Tifft, C.J., and Eichler, F.S. 2011. Natural history of infantile G(M2) gangliosidosis. Pediatrics 128:e1233‐e1241.
  Cao, Z., Petroulakis, E., Salo, T., and Triggs‐Raine, B. 1997. Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause beta‐hexosaminidase A pseudodeficiency by reducing the alpha‐subunit protein levels. J. Biol. Chem. 272:14975‐14982.
  Chamoles, N.A., Blanco, M., Gaggioli, D., and Casentini, C. 2002. Tay‐Sachs and Sandhoff diseases: Enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn‐screening cards. Clin. Chim. Acta 318:133‐137.
  Clarke, J.T., Mahuran, D.J., Sathe, S., Kolodny, E.H., Rigat, B.A., Raiman, J.A., and Tropak, M.B. 2011. An open‐label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay‐Sachs or Sandhoff variants). Mol. Genet. Metab. 102:6‐12.
  D'Souza, G., McCann, C.L., Hedrick, J., Fairley, C., Nagel, H.L., Kushner, J.D., and Kessel, R. 2000. Tay‐Sachs disease carrier screening: A 21‐year experience. Genet. Test. 4:257‐263.
  Ekstein, J. and Katzenstein, H. 2001. The Dor Yeshorim story: Community‐based carrier screening for Tay‐Sachs disease. Adv. Genet. 44:297‐310.
  Fitterer, B., Hall, P., Antonishyn, N., Desikan, R., Gelb, M., and Lehotay, D. 2014. Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis. Mol. Genet. Metab. 111:382‐389.
  Kaback, M. and Zeiger, R. 1972. Heterozygote detection in Tay‐Sachs disease: A prototype community screening program for the prevention of recessive genetic disorders. In Sphingolipids, Sphingolipidoses and Allied Disorders, (B. Volk and S. Aronson, eds.) p. 613. Plenum Press, New York.
  Kampine, J.P., Brady, R.O., Kanfer, J.N., Feld, M., and Shapiro, D. 1967. Diagnosis of Gaucher's disease and Niemann‐Pick disease with small samples of venous blood. Science 155:86‐88.
  Lowden, J.A., Zuker, S., Wilensky, A.J., and Skomorowski, M.A. 1974. Screening for carriers of Tay‐Sachs disease: A community project. Can. Med. Assoc. J. 111:229‐233.
  Lowden, J.A., Ives, E.J., Keene, D.L., Burton, A.L., Skomorowski, M.A., and Howard, F. 1978. Carrier detection in Sandhoff disease. Am. J. Hum. Genet. 30:38‐45.
  Maegawa, G.H., Tropak, M., Buttner, J., Stockley, T., Kok, F., Clarke, J.T., and Mahuran, D.J. 2007. Pyrimethamine as a potential pharmacological chaperone for late‐onset forms of GM2 gangliosidosis. J. Biol. Chem. 282:9150‐9161.
  Mahuran, D.J. 1999. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim. Biophys. Acta 1455:105‐138.
  O'Brien, J.S., Okada, S., Chen, A., and Fillerup, D.L. 1970. Tay‐Sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N. Engl. J. Med. 283:15‐20.
  Osher, E., Fattal‐Valevski, A., Sagie, L., Urshanski, N., Amir‐Levi, Y., Katzburg, S., Peleg, L., Lerman‐Sagie, T., Zimran, A., Elstein, D., Navon, R., Stern, N., and Valevski, A. 2011. Pyrimethamine increases beta‐hexosaminidase A activity in patients with Late Onset Tay Sachs. Mol. Genet. Metab. 102:356‐363.
  Patterson, M.C. 2013. Gangliosidoses. Handb. Clin. Neurol. 113:1707‐1708.
  Saifer, A. and Perle, G. 1974. Automated determination of serum hexosaminidase A by pH inactivation for detection of Tay‐Sachs disease heterozygotes. Clin. Chem. 20:538‐543.
  Saifer, A., Parkhurst, G.W., and Amoroso, J. 1975. Automated differentiation and measurement of hexosaminidase isoenzymes in biological fluids and its application to pre‐ and postnatal detection of Tay‐Sachs disease. Clin. Chem. 21:334‐342.
  Triggs‐Raine, B.L., Mules, E.H., Kaback, M.M., Lim‐Steele, J.S., Dowling, C.E., Akerman, B.R., Natowicz, M.R., Grebner, E.E., Navon, R., Welch, J.P., et al. 1992. A pseudodeficiency allele common in non‐Jewish Tay‐Sachs carriers: Implications for carrier screening. Am. J. Hum. Genet. 51:793‐801.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library